Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791283 | 0.83 | OPRM1 (0.38) | ILKKDRBTK | |
| SCHEMBL23356009 | 0.83 | OPRM1 (0.38) | ILKKDRBTK | |
| SCHEMBL30791220 | 0.82 | NUDT1 (0.43) | ALDH1A1GAAMAPTKDM4ELMNA | |
| SCHEMBL23356011 | 0.82 | NUDT1 (0.43) | ALDH1A1GAAMAPTKDM4ELMNA | |
| SCHEMBL30791228 | 0.80 | MAPT (0.44) | GAAMAPTP2RX7LMNAKMT2A | |
| SCHEMBL23356026 | 0.80 | MAPT (0.44) | GAAMAPTP2RX7LMNAKMT2A | |
| SCHEMBL30791219 | 0.78 | ZAP70 (0.36) | ILKP2RX7 | |
| SCHEMBL23356137 | 0.78 | ZAP70 (0.36) | ILKP2RX7 | |
| SCHEMBL23369587 | 0.78 | DHODH (0.42) | P2RX7KDR | |
| SCHEMBL23356139 | 0.75 | EGFR (0.44) | ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
| EP-3822270-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW Pharmaceutical Corporation (KR) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | ILK 1593/4885ALDH1A1 1733/4885GAA 4760/4885 |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | ILK 3880/4885ALDH1A1 734/4885GAA 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.